MDR 103

Drug Profile

MDR 103

Alternative Names: MDR-103

Latest Information Update: 17 May 2017

Price : $50

At a glance

  • Originator Medeor Therapeutics
  • Class Cell therapies; Immunotherapies; Stem cell therapies; T lymphocyte cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Renal transplant rejection

Most Recent Events

  • 11 May 2017 Medeor Therapeutics plans a phase II trial for Renal transplant rejection (In existing living donor kidney transplant recipients) in USA (Medeor Therapeutics' website, May 2017)
  • 11 May 2017 Phase-I clinical trials in Renal transplant rejection in USA (Parenteral) (Medeor Therapeutics' website, May 2017)
  • 28 Apr 2017 Medeor Therapeutics has patent protection for technology underlying the manufacturing process of its therapies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top